Shares of Oscar Health (OSCR) jumped Wednesday, the latest big gain for the health insurer after Piper Sandler analysts upgraded their rating of the stock in a recent note to clients.
Oscar Health stock (NYSE: OSCR) has recently increased to over $16 after reports of a possible two-year extension of Obamacare subsidies, which may positively influence demand for health insurance via the Affordable Care Act (ACA) Marketplace. This surge signifies investor confidence regarding imminent policy support, yet the central question persists: Is OSCR stock still an enticing purchase following its recent increase?
Mark Bertolini, Oscar Health CEO, Verizon chairman and former Aetna chairman and CEO, joins 'Squawk Box' to discuss the state of the health insurance industry, why insurance premiums are going up, future of the ACA, skyrocketing health care costs, ways to fix the U.S. health care system, and more.
Oscar Health saw its stock price surge from $13.82 to $23.80, marking a 70% increase since August. The stock has since corrected, primarily due to concerns related to the Affordable Care Act (ACA). Despite the pullback, OSCR still reflects a 28% appreciation since the previous analysis.
Oscar Health Inc (NYSE:OSCR) is sitting out today's broad market rally , last seen down 15.9% to trade at $14.98.
Oscar Health, Inc. ( OSCR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Chris Potochar - Vice President of Treasury & Investor Relations Mark Bertolini Richard Blackley - Chief Financial Officer Mark Bertolini - CEO & Director Conference Call Participants Hua Ha - Robert W. Baird & Co. Incorporated, Research Division Joshua Raskin - Nephron Research LLC Jessica Tassan - Piper Sandler & Co., Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Jonathan Yong Andrew Mok - Barclays Bank PLC, Research Division Craig Jones - BofA Securities, Research Division Steven Couche Presentation Operator Good morning.
The headline numbers for Oscar Health (OSCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Oscar Health, Inc. (OSCR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.22 per share a year ago.
Oscar Health Thursday reported a $137 million third quarter loss but predicts “a return to profitability” as the health insurance industry works its way through a period of rising costs and Washington gridlock.
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $21.03, denoting a +1.74% move from the preceding trading day.
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $21.8, indicating a -2.98% shift from the previous trading day.
Oscar Health (OSCR) faces uncertainty as the expiration of enhanced ACA premium tax credits could impact membership and margins. Oscar's growth is supported by rising Individual Coverage Health Reimbursement Arrangements (ICHRA), expanding its addressable market and revenue potential. If subsidies are extended, Oscar will able to continue to grow their member base and eventually reach profitability.